Tempus AI (Nasdaq: TEM) Earnings: Live Coverage And What to Expect

Tempus’ business is structured across three pillars, each with distinct growth and margin profiles.

• Clinical Testing: This is the company’s legacy business, providing genomic and diagnostic tools to physicians. Retention and volume growth remain key.

• Pharma SaaS: Analysts view this as the highest-margin growth engine. It includes software and platform offerings for biopharma companies running trials or developing precision therapeutics.

• Data Licensing & Insights: A newer and strategic area, this segment involves monetizing Tempus’ real-world data with partners — especially in international markets.

• AI Platform Integration: Investors want clarity on how the AI engine is being adopted across pharma and hospital systems, including any modular offerings or new client onboarding milestones.

Tempus AI carries an average analyst price target of $61.40, with a tight range between $48 and $74, indicating strong consensus around near-term execution potential. Analysts highlight Tempus’ leadership in real-world evidence and precision medicine, along with a growing pipeline of pharma SaaS and data licensing deals.

With FY2025 revenue guidance at $1.24 billion, expectations are high for steep topline growth, but the valuation — over 20x forward sales — means performance must stay on track. The stock’s surge post-IPO has caught institutional attention, but ongoing scrutiny around margins and churn will likely shape future price target revisions.

Expect price target shifts based on updates to customer expansion, full-year EBITDA guidance, and contract renewal commentary.

• Q1 2025 Revenue: $248.1 million

• GAAP EPS Estimate: $(0.27)

• Adjusted EBITDA: $(21.7 million)

• Gross Margin: 58.8%

• FY2025 Revenue Guidance: $1.24 billion

• Average Analyst Price Target: $61.40

  • Range: $48.00 – $74.00

Expectations imply steep topline growth and widening platform adoption, with close attention on EBITDA progress and contract retention.

Tempus AI enters Q1 2025 earnings riding strong investor momentum, with shares up over 80% in the past six months, according to recent trading data. The company has benefited from heightened interest in AI-powered healthcare tools and real-world evidence platforms, especially among institutional buyers in biotech and digital health.

Recent announcements highlight partnerships with academic medical centers and global pharmaceutical firms, helping Tempus expand both its clinical testing volumes and enterprise software footprint. Analysts are closely watching churn metrics, net revenue retention, and traction in the biopharma SaaS segment, which has become a key pillar of growth.

While optimism is high, the company’s valuation — over 20x forward revenue — puts pressure on execution. Investors will look for confirmation that Tempus is converting pilot projects into recurring, high-margin contracts, and expanding its platform internationally with sustainable economics.